NO20023402D0 - Mixtures and Methods for the Treatment and Diagnosis of Prostate Cancer - Google Patents

Mixtures and Methods for the Treatment and Diagnosis of Prostate Cancer

Info

Publication number
NO20023402D0
NO20023402D0 NO20023402A NO20023402A NO20023402D0 NO 20023402 D0 NO20023402 D0 NO 20023402D0 NO 20023402 A NO20023402 A NO 20023402A NO 20023402 A NO20023402 A NO 20023402A NO 20023402 D0 NO20023402 D0 NO 20023402D0
Authority
NO
Norway
Prior art keywords
diagnosis
mixtures
treatment
methods
prostate cancer
Prior art date
Application number
NO20023402A
Other languages
Norwegian (no)
Other versions
NO20023402L (en
Inventor
Jiangchun Xu
Davin C Dillon
Jennifer Lynn Mitcham
Susan L Harlocker
Yuqiu Jiang
Steven G Reed
Michael D Kalos
Gary Richard Fanger
Craig H Day
Marc W Retter
John A Stolk
Yasir A W Skeiky
Aijun Wang
Madeleine Joy Meagher
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of NO20023402D0 publication Critical patent/NO20023402D0/en
Publication of NO20023402L publication Critical patent/NO20023402L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4275—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20023402A 2000-01-14 2002-07-15 Mixtures and Methods for the Treatment and Diagnosis of Prostate Cancer NO20023402L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48367200A 2000-01-14 2000-01-14
PCT/US2001/001574 WO2001051633A2 (en) 2000-01-14 2001-01-16 Compositions and methods for the therapy and diagnosis of prostate cancer

Publications (2)

Publication Number Publication Date
NO20023402D0 true NO20023402D0 (en) 2002-07-15
NO20023402L NO20023402L (en) 2002-08-29

Family

ID=23921037

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023402A NO20023402L (en) 2000-01-14 2002-07-15 Mixtures and Methods for the Treatment and Diagnosis of Prostate Cancer

Country Status (16)

Country Link
EP (1) EP1261708A2 (en)
JP (1) JP2003528591A (en)
KR (1) KR20030016217A (en)
CN (1) CN1436234A (en)
AU (1) AU3447401A (en)
BR (1) BR0107643A (en)
CA (1) CA2397741A1 (en)
CZ (1) CZ20022756A3 (en)
HU (1) HUP0203968A3 (en)
IL (1) IL150732A0 (en)
MX (1) MXPA02006934A (en)
NO (1) NO20023402L (en)
PL (1) PL356908A1 (en)
RU (1) RU2002121771A (en)
WO (1) WO2001051633A2 (en)
ZA (1) ZA200206400B (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125536A1 (en) * 1996-01-11 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
AU7019498A (en) 1997-04-10 1998-10-30 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US6861215B1 (en) 1998-05-21 2005-03-01 Diadexus, Inc. Method of diagnosing, monitoring, and staging prostate cancer
DE69941187D1 (en) 1998-06-01 2009-09-10 Agensys Inc SERPENTINTRANSMEMBRANANTIGENE EXPRESSED IN HUMAN CANCER AND ITS USES
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US7022497B1 (en) 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
DK1222266T3 (en) 1999-09-29 2006-07-10 Diagnocure Inc PCA3 messenger RNA in benign and malignant prostate tissue
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
EP1517913B9 (en) * 1999-10-07 2007-08-29 Corixa Corporation A mycobacterium tuberculosis coding sequence for exression of heterologous proteins
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
WO2001073032A2 (en) * 2000-03-27 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
PT2133100E (en) 2000-06-20 2012-01-11 Corixa Corp Mtb32a antigen of mycobacterium tuberculosis with inactivated active site and fusion proteins thereof
AU2001281322A1 (en) * 2000-07-13 2002-01-30 Biogen, Inc. Methods of identifying renal protective factors
WO2002010382A2 (en) * 2000-07-28 2002-02-07 Ulrich Wissenbach Trp8, trp9 and trp10, markers for cancer
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1573024A4 (en) 2001-04-10 2007-08-29 Agensys Inc NUCLEIC ACIDS AND CORRESPONDING PROTEINS USEFUL FOR THE DETECTION AND TREATMENT OF VARIOUS CANCERS
CA2446788A1 (en) * 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
EP1409549A4 (en) * 2001-06-20 2007-10-24 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003022995A2 (en) * 2001-09-06 2003-03-20 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
AU2003210663A1 (en) 2002-01-25 2003-09-02 The Regents Of The University Of California Methods of modulating cold sensory perception
DE10215321A1 (en) * 2002-04-02 2003-10-23 Metagen Pharmaceuticals Gmbh New nucleic acid encoding Trpp8 splice variants, useful for diagnosis of prostatic cancer, and to screen for diagnostic or therapeutic agents, also related proteins
RU2004135541A (en) * 2002-06-11 2005-10-10 ГлаксоСмитКлайн Байолоджикалз с.а. (BE) IMMUNOGENIC COMPOSITIONS
DE10234901A1 (en) * 2002-07-26 2004-02-12 Metagen Pharmaceuticals Gmbh New nucleic acids encoding Mrp4, useful in the diagnosis of prostatic, bladder and ovarian tumors, also in screening for specific binding agents, and potential therapeutic agents
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
JP4824540B2 (en) 2003-02-07 2011-11-30 ダイアノキュアー インク． How to detect prostate cancer in a sample
BRPI0418766B8 (en) 2004-04-22 2021-05-25 Agensys Inc antibody or fragment thereof, vector, pharmaceutical composition, assay and method for detecting the presence of step-1 protein, as well as a method for delivering a cytotoxic agent or a diagnostic agent
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
JP4969444B2 (en) * 2005-06-14 2012-07-04 ディナベック株式会社 Antibody production method
PT2845866T (en) 2006-10-27 2017-08-09 Genentech Inc ANTIBODIES AND IMMUNOCONUELS AND UTILIZATIONS THEREOF
SG10201806573TA (en) * 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
CN104357451B (en) * 2014-12-02 2016-09-21 广州市番禺区中心医院 For the siRNA of DD3 gene and expression vector establishment thereof and application
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201520566D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CN110325205B (en) * 2016-12-22 2023-08-15 库尔生物制药有限公司 T cell modulating multimeric polypeptides and methods of use thereof
PE20200010A1 (en) 2017-04-03 2020-01-06 Hoffmann La Roche ANTIBODIES THAT JOIN STEAP-1
CN110988348B (en) * 2019-11-06 2022-07-05 北京九强生物技术股份有限公司 Free prostate specific antigen detection kit and preparation method thereof
CA3185241A1 (en) * 2020-07-13 2022-01-20 Noam LEVIN Hla class ii?restricted drb t cell receptors against ras with g12d mutation
JP2024501482A (en) * 2020-12-14 2024-01-12 ビオンテック ユーエス インコーポレイテッド Tissue-specific antigens for cancer immunotherapy
CN114250238B (en) * 2021-11-26 2023-08-25 北京航空航天大学 Gene-encoded neuron development regulatory polypeptide and its application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4600637A1 (en) * 1996-03-15 1998-05-08 Corixa Corp COMPOUNDS FOR IMMUNOTHERAPY AND IMMUNODIAGNOSIS OF CANCER OF PROSTATE
EP1005546A2 (en) * 1997-02-25 2000-06-07 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
CA2281954A1 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
TR200100916T2 (en) * 1998-07-14 2002-06-21 Corixa@@Corporation
WO2001025272A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
AU1656501A (en) * 1999-11-12 2001-06-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer

Also Published As

Publication number Publication date
NO20023402L (en) 2002-08-29
IL150732A0 (en) 2003-02-12
PL356908A1 (en) 2004-07-12
AU3447401A (en) 2001-07-24
EP1261708A2 (en) 2002-12-04
RU2002121771A (en) 2004-03-10
CA2397741A1 (en) 2001-07-19
HUP0203968A3 (en) 2004-09-28
MXPA02006934A (en) 2003-01-28
CN1436234A (en) 2003-08-13
ZA200206400B (en) 2004-01-21
BR0107643A (en) 2003-06-10
HUP0203968A2 (en) 2003-03-28
WO2001051633A2 (en) 2001-07-19
KR20030016217A (en) 2003-02-26
JP2003528591A (en) 2003-09-30
CZ20022756A3 (en) 2003-02-12
WO2001051633A3 (en) 2002-06-20
WO2001051633A9 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
NO20030714D0 (en) Mixtures and Methods for the Treatment and Diagnosis of HER-2 / NEU-Associated Malignancies
NO20013002L (en) Mixtures and methods for the treatment and diagnosis of ovarian cancer
NO20024972L (en) Mixtures and Methods for Therapy and Diagnosis of Breast Cancer
NO20010196D0 (en) Compositions and Methods for Therapy and Diagnosis of Prostate Cancer
NO20016427D0 (en) Compositions and Methods for the Treatment of Diagnosis of Lung Cancer
NO20014769D0 (en) Preparation for the treatment and diagnosis of breast cancer and methods for its use
NO983183L (en) Mixtures and Procedures for the Treatment and Diagnosis of Breast Cancer
HUP0203968A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
NO20003853D0 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
DK1587837T3 (en) Epitope sequences for the diagnosis and treatment of prostate cancer
NO20022592D0 (en) Compounds and Methods for the Treatment and Diagnosis of Chlamydia Infections
EP1515982A4 (en) METHODS AND COMPOSITIONS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
AU2003302892A8 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
DK200001852A (en) Manipulation section for an endoscopic treatment instrument
NO20043246L (en) New methods for the diagnosis and treatment of tumors
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
IS6918A (en) Treatment of difficult tumors with the use of epothilone derivatives
IS6917A (en) Epothilone derivatives for the treatment of difficult tumors
AU2002246519A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
EP1320376A4 (en) TREATMENT OF PROSTATE CANCER
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
NO20014804D0 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
NO20025594D0 (en) Mixtures and Methods for Therapy and Diagnosis of Breast Cancer
NO20014805L (en) Mixtures and Methods for Treating and Diagnosing Breast Cancer
EP1349485A4 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application